Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens
The Oncologist · 03.06.2024 · 29 (6) · 465-472
DOI: 10.1093/oncolo/oyae060 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 17.04.2024. Verfasst von Priscila Radu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Office of Health Economics, London, United Kingdom. Hauptthemen laut MEDLINE: Precision Medicine, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Federation of Pharmaceutical Industries and Associations.
Abstract (Originalsprache)
Background
Genomic and molecular alterations are increasingly important in cancer diagnosis, and scientific advances are opening new treatment avenues. Precision oncology (PO) uses a patient’s genomic profile to determine optimal treatment, promising fewer side effects and higher success rates. Within PO, tumor-agnostic (TA) therapies target genomic alterations irrespective of tumor location. However, traditional value frameworks and approval pathways pose challenges which may limit patient access to PO therapies.
Objectives
This study describes challenges in assessing PO and TA medicines, explores possible solutions, and provides actionable recommendations to facilitate an iterative life-cycle assessment of these medicines.
Methods
After reviewing the published literature, we obtained insights from key stakeholders and European experts across a range of disciplines, through individual interviews and an industry workshop. The research was guided and refined by an international expert committee through 2 sounding board meetings.
Results
The current challenges faced by PO and TA medicines are multiple and can be demonstrated through real-world examples of the current barriers and opportunities. A life-cycle approach to assessment should be taken, including key actions at the early stages of evidence generation, regulatory and reimbursement stage, as well as payment and adoption solutions that make use of the evolving evidence base. Working toward these solutions to maximize PO medicine value is a shared responsibility and stands to benefit all stakeholders.
Conclusions
Our call to action is to expand access to comprehensive genomic testing, foster a learning health care system, enable fast and equitable access to cost-effective treatments, and ultimately improve health outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Office of Health Economics, London, United Kingdom.
- Global Oncology Policy, GSK, London, United Kingdom.
- Global Access Strategy Oncology, Roche, San Francisco, CA, United States.
- Department of Health Economics, Ghent University, Ghent, Belgium.
- Patvocates, Munich, Germany.
- Early Phase Trials and Sarcoma Units, Institut Bergonié, Bordeaux, France.
ORCID-Profile: Priscila Radu, Lieven Annemans
Förderung
- European Federation of Pharmaceutical Industries and Associations
Zitieren
APA
Radu, P., Kumar, G., Cole, A., Fameli, A., Guthrie, M., Annemans, L., Geissler, J., Italiano, A., O'Rourke, B., Xoxi, E., & Steuten, L. (2024). Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens. The Oncologist, 29(6), 465-472. https://doi.org/10.1093/oncolo/oyae060
Vancouver
Radu P, Kumar G, Cole A, Fameli A, Guthrie M, Annemans L, et al. Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens. The Oncologist. 2024;29(6):465-472. doi:10.1093/oncolo/oyae060
BibTeX
@article{Radu2024,
author = {Radu, Priscila and Kumar, Gayathri and Cole, Amanda and Fameli, Aikaterini and Guthrie, Mark and Annemans, Lieven and Geissler, Jan and Italiano, Antoine and O'Rourke, Brian and Xoxi, Entela and Steuten, Lotte},
title = {Evolving assessment pathways for precision oncology medicines to improve patient access: a tumor-agnostic lens},
journal = {The Oncologist},
year = {2024},
volume = {29},
number = {6},
pages = {465--472},
doi = {10.1093/oncolo/oyae060}
}
EUVIMED